Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01473407 | A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin | PHASE3 | COMPLETED | 612 | — | — | Jan 31, 2012 | Feb 11, 2014 | Sep 10, 2018 | 85 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| Epoetin Hospira | EXPERIMENTAL | Epoetin Hospira |
| Epogen (Amgen) | ACTIVE_COMPARATOR | Epogen (Amgen) |
| Name | Type | Description |
|---|---|---|
| Epoetin Hospira | BIOLOGICAL | Variable dose |
| Epogen (Amgen) | BIOLOGICAL | Variable dose |
Inclusion Criteria: 1. Patient is able to provide written informed consent after risks and benefits of the study have been explained prior to any study related activities 2. Hemodialysis patients with chronic renal failure and renal anemia currently on stable Epogen (Amgen) treatment for at least 4...